InSilico Medicine Cayman TopCo (3696.HK) Stock Forecast 2027, 2031 & 7-Year Price Prediction
Get the latest InSilico Medicine Cayman TopCo (3696.HK) stock forecast across short-term and long-term horizons. Meyka AI generates price predictions using advanced models trained on historical data. These forecasts are not investment advice but directional insights to help investors and traders plan strategies.
InSilico Medicine Cayman TopCo (3696.HK)
Model Information
The Forecast Prediction Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerMonthly Forecast
Quarterly Forecast
Yearly Forecast
3 Years Forecast
5 Years Forecast
7 Years Forecast
InSilico Medicine Cayman TopCo Stock Forecast Summary
InSilico Medicine Cayman TopCo (3696.HK) stock is currently priced at $45.90. Based on Meyka AI predictions, the short-term outlook is bearish, with momentum pointing higher. The 1-month projection suggests a move toward $41.97.
In the long term, 3696.HK shows a bullish trend. The 2027 forecast points to $53.79 (17.19% change), while the 2031 forecast suggests $93.77 (104.29% change). Looking 7 years ahead, projections estimate the stock could trade near $109.77, a 139.15% change from today’s price.
Neutral
Bearish
Bullish
This mix indicates that InSilico Medicine Cayman TopCo stock is expected to rise steadily over the coming years.
Investment Calculator
Estimate your potential returns on 3696.HK using our advanced Investment Calculator with AI-driven price forecasts. Enter your investment amount and select a target date to view expected results, including estimated profit, loss, and ROI performance.
Based on your investment of HK$1,000.00 in InSilico Medicine Cayman TopCo and holding until July 22nd, 2027, you could face a potential +HK$171.91 profit, reflecting a +17.2% ROI over the next 365 days. These projections help you better understand short-term market movements.
$Shares Bought
21.7865
@ HK$45.90/share
~Forecast Price
HK$53.79
1-year AI forecast
$Est. Portfolio Value
HK$1,171.91
+HK$171.91 profit
%ROI
+17.2%
return on investment
InSilico Medicine Cayman TopCo yearly Price Forecast Chart
Explore the yearly forecast chart for 3696.HK, which maps expected price movement, support levels, and resistance targets. The dropdown lets you view forecasts across multiple horizons, from short-term daily trends to 7-year projections, helping investors evaluate InSilico Medicine Cayman TopCo over different timeframes.
No forecast data available
No prediction data found for this time period.
Forecasting data is not available for 3696.HKForecasting details for 3696.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.InSilico Medicine Cayman TopCo Stock Forecast 2026
The forecast for InSilico Medicine Cayman TopCo (3696.HK) in 2026 suggests a price of $53.79, representing a 17.19% move from today’s price.
Average Target: $53.79
Market Outlook: bullish based on current trend indicators.
Key Drivers in 2026:- Earnings growth projections.
- Competitive performance in the Technology.
- Macroeconomic factors such as interest rates and inflation.
InSilico Medicine Cayman TopCo Stock Forecast 2030
By 2030, Meyka AI projects 3696.HK could trade near $93.77, showing a potential 104.29% compared to current levels.
Average Target: $93.77
Market Outlook: bullish.
What could influence the 2030 forecast:- Technological innovation and product cycles.
- Expansion into global markets.
- Long-term investor sentiment toward InSilico Medicine Cayman TopCo.
InSilico Medicine Cayman TopCo 7-Year Stock Forecast (2032–2033)
Looking 7 years ahead, the long-term forecast for 3696.HK points to a price around $109.77, which is a projected 139.15% move from today’s level.
Average Target: $109.77
Outlook: bullish, depending on macroeconomic conditions and sector growth.
Long-Term Drivers:- Global economic expansion or contraction.
- Regulatory and policy environment.
- InSilico Medicine Cayman TopCo’s ability to maintain market leadership.